Drug Trial Radar · NCT02187159
Treatment of Pain Associated With Fibromyalgia
Last checked: Nov 20, 2026Latest source record: Nov 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,270
Actual
Start
Nov 2014
Primary completion
Jul 7, 2016
Study completion Jul 7, 2016
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Syneos Health
- First posted
- Jul 10, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain over the previous 24 hours.
Conditions
- Pain Associated With Fibromyalgia
Interventions
DS-5565Drug
DS-5565 15 mg tablet for oral administration
PregabalinDrug
Pregabalin 150 mg capsule for oral administration
Placebo tabletDrug
Placebo tablet (matching DS5565) for oral administration
Placebo capsuleDrug
Placebo capsule (matching pregabalin) for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) in Participants Receiving DS-5565, Pregabalin, or PlaceboTime frame: Baseline up to Week 13 postdose
Locations
176 sites in 12 countries. Site status is shown where the registry gives one.
Site not named
Mobile, Alabama
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Little Rock, Arkansas
Site not named
Fresno, California
Site not named
Glendale, California
Site not named
Orange, California
Site not named
Oxnard, California
Site not named
Richmond, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
Santa Ana, California
Site not named
Santa Barbara, California
Site not named
Simi Valley, California
Site not named
New London, Connecticut
Site not named
Bradenton, Florida
Site not named
Brandon, Florida
Site not named
DeBary, Florida
Site not named
Fort Myers, Florida
Site not named
Hialeah, Florida
Site not named
Homestead, Florida
Site not named
Lake Mary, Florida
Site not named
Miami, Florida
Site not named
North Miami, Florida
Site not named
Ocala, Florida
Site not named
Plant City, Florida
Site not named
Tampa, Florida
Site not named
Alpharetta, Georgia
Site not named
Atlanta, Georgia
Site not named
Atlanta, Georgia
Site not named
Columbus, Georgia
Site not named
Savannah, Georgia
Site not named
Boise, Idaho
Site not named
Meridian, Idaho
Site not named
Chicago, Illinois
Site not named
Gurnee, Illinois
Site not named
Naperville, Illinois
Site not named
Evansville, Indiana
Site not named
West Des Moines, Iowa
Site not named
Shawnee Mission, Kansas
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.